Effect of atenolol on hemoglobin level in mild to moderate hypertension
Keywords:Hemoglobin level, Hypertension, Packed cell volume, Sympathetic overactivity
Background: Hypertension is the most common cardiovascular disease and a major cardiovascular risk factor that causes significant morbidity and mortality worldwide. Most common type is primary (essential) hypertension and is genetically determined. It affects many systems of the body and can also alter various hematological parameters. The study was undertaken to check the effect of atenolol on hemoglobin (Hb) level in mild to moderate hypertension.
Methods: The study was prospective and non-randomized. Thirty newly diagnosed hypertensives selected for atenolol therapy by medicine personnel were enrolled in the study based on inclusion and exclusion criteria. Patients were divided into pre-treatment (before starting atenolol therapy) and post-treatment group. Red blood cell (RBC) count, Hb, packed cell volume (PCV) and red cell indices were measured at the time of enrolment and then monthly after starting atenolol for next 3 months.
Result: Results were analyzed by repeated measure analysis of variance. Atenolol treatment was found to increase Hb and PCV significantly, whereas no significant change in RBC count and red cell indices.
Conclusions: Treatment with atenolol for mild to moderate hypertension has shown a significant increase in Hb and PCV level. This positive effect may be because of the decrease in sodium and water reabsorption by decrease in sympathetic overactivity and excretion of sodium and water by improvement in kidney functions. Atenolol has no any direct effect on Hb synthesis and erythropoiesis.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23.
Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens. 2004;18(2):73-8.
Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation. 2000;101(3):329-35.
Julius S, Nesbitt S. Sympathetic overactivity in hypertension. A moving target. Am J Hypertens. 1996;9(11):113S-20.
Fogari R, Zoppi A. Is sympathetic hyperactivity a coronary risk factor? Cardiologia. 1993;38 12 Suppl 1:427-34.
Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J. 1998;19 Suppl F: F14-8.
Julius S. The evidence for a pathophysiologic significance of the sympathetic overactivity in hypertension. Clin Exp Hypertens. 1996;18(3-4):305-21.
Dutt AR, Ramaswamy C, Niranjan Murthy HL, Satish Kumar NS, Shankar Bhat K. Do hypertensives have tendency for lesser hemoglobin concentration? Natl J Basic Med Sci. 2010;1:65-9.
Jadeja U, Jadeja JM, Naik S. Comparative study of haemoglobin concentration in hypertensive and normotensive subjects. Indian J Appl Basic Med Sci. 2011;13(17):7.
Hall JE, Granger JP, do Carmo JM, da Silva AA, Dubinion J, George E, et al. Hypertension: physiology and pathophysiology. Compr Physiol. 2012;2(4):2393-442.
Somers VK. Cardiovascularmenifestations of autonomic disoders. In: Bonow M, Zipes DP, Libby P, editors. 9th Edition. India: Elsevier; 2011: 13.
Howard BV, Curb JD, Eaton CB, Kooperberg C, Ockene J, Kostis JB, et al. Low-fat dietary pattern and lipoprotein risk factors: the Women’s Health Initiative Dietary Modification Trial. Am J Clin Nutr. 2010;91(4):860-74.
Schlaich MP, Bart B, Hering D, Walton A, Marusic P, Mahfoud F, et al. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol. 2013;168(3):2214-20.
Smebye ML, Iversen EK, Høieggen A, Flaa A, Os I, Kjeldsen SE, et al. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study). Am J Cardiol. 2007;100(5):855-9.
Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, et al. Hemodilution is common in patients with advanced heart failure. Circulation. 2003;107(2):226-9.
Efstratiadis G, Konstantinou D, Chytas I, Vergoulas G. Cardio-renal anemia syndrome. Hippokratia. 2008;12(1):11-6.
Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26(21):2232-7.
Guidi GC, Lechi Santonastaso C. Advancements in anemias related to chronic conditions. Clin Chem Lab Med. 2010;48(9):1217-26.
Kes P, Basic-Jukic N, Juric I, Basic-Kes V. The cardiorenal syndrome and erythropoietin. Acta Med Croatica. 2008;62 Suppl 1:21-31.
Silverberg DS, Wexler D, Iaina A, Schwartz D. Anaemia management in cardio renal disease. J Ren Care. 2010;36 Suppl 1:86-96.
Silverberg DS. The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome. Heart Fail Rev. 2011;16(6):609-14.
Kotchen TA. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jamsen JL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 18th Edition. New York: McGraw Hill; 2012: 18.
Adlbrecht C, Kommata S, Hülsmann M, Szekeres T, Bieglmayer C, Strunk G, et al. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body’s red cell volume. Eur Heart J. 2008;29(19):2343-50.
Special Issue on Indian Guidelines on Hypertension (I.G.H.)-III, February 2013, Vol. 61. What is New in Indian Guidelines on Hypertension – III, 2013. Available from: http://www.japi.org/february_2013_special_issue_hypertension_guidelines/03_what_is_new_in.html. [Last accessed on 2014 June 20].